|
|
St. Louis, MO USA
phone:
fax:
|
|
| Symbol |
Private |
| Founded |
2007 |
| Employees |
|
|
|
| www.vasculox.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Cardiovascular Therapeutics for Regulation of Nitric Oxide Signaling |
|
| Management |
| Thomas J. Brya, CEO and President; William A. Frazier, Ph.D. Chief Scientific Officer; Pamela T. Manning, Ph.D. Vice President of Research and Development; Robert W. Kurzu, MBA, Administrative Officer |
| |
|
|
| |
|
| Keywords |
| Cardiology, Diabetes, Immunology. Nitric Oxide (NO), Tissue Ischemia, Hypertension, Atherosclerosus, Diabetic Vasculopathy, Metabolic Syndrome |
|
|
|
| Description |
|
Vasculox, Inc. is a pharmaceutical discovery and development company focused on the development of proprietary drugs for the treatment of cardiovascular disease, particularly those relating to or caused by tissue ischemia. |
|
| Products / Services |
Products currently under development provide several ways of releasing the TSP1/CD47 brake on nitric oxide production. These include an anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide and a small molecule CD47 inhibitor.
|
|
| Technology / Differentiation |
| Our platform technology is based on a novel vascular regulatory system consisting of thrombospondin-1 and its receptor, CD47. This system arose during evolution of verebrates to promote the life-saving function of hemostasis at a time when death by trauma and predation was the fate of most organisms. CD47 promotes blood clotting by stimulating platelet activation and aggregation and by causing local vasoconstriction. Today in the context of our longer lives, rich diets and sedentary lifestyles, the TSP1-CD47 system's ability to put a brake on nitric oxide signaling opposes many healthful effects of nitric oxide throughout the cardiovascular system. As demonstrated through extensive in vivo preclinical studies, inhibition of CD47 can provide a unique therapeutic benefit to ischemic tissues via an immediate vasodilatory response, as well as through a pro-angiogenic effect. |
|
|
| Status |
| Vasculox has received STTR grants from the NIH to develop its humanized monoclonal antibody for the treatment of diseases associated with tissue ischemia and to commence proof-of-concept studies investigating the use of its therapy in early-stage liver transplantation. Licensing agreements are underway. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members